Diagnosis

Rosacea

A chronic skin disease that causes transient facial flushing, erythema, papules, pustules and telangiectasias with central face distribution.

Etiology

Cause [szn]

Pathophysiology [r3a][szn]

  1. Neurovascular dysregulation:

    • Dilation of lymphatic and blood vessels --> erythema and flushing

  2. Inflammatory activation:

    • Chronic low-grade dermatitis --> neoangiogenesis

    • Dermal matrix degeneration

    • Pilosebaceous unit abnormalities

    • Reactive oxygen species

  3. Subtypes: [znn][szn]

    • Erythematotelangiectatic: Persistent erythema with intermittent flushing

    • Papulopustular: Papules and pustules ("adult acne" without comedones)

    • Phymatous: Fibrosis and hypertrophy of sebaceous glands (male nose)

    • Ocular affection (50-75%): Redness, tearing, dry eye, tingling/burning, foreign-body sensation, light sensitivity, blurred vision, gritty sensation, pruritus, hordeola, and blepharitis

Epidemiology

Prevalence per 100.000 [mgd][qzu][edf][f3p]

Epidemiology chart for Prevalence

Symptoms & findings

Symptoms

Blepharitis, Conjunctivitis, Xerophthalmia

Clinical findings

None listed.

Anamneses

None listed.

Localized findings

Rash
Radiates
Caput
Distribution
MultipleSymmetric
Lesion type
ErythemaPapulePlaquePustuleScaleTelangiectasia
Color
Red
Associated symptom
PainSwelling
Palpation
Pain

Approach

Diagnostic criteria [znn]

Treatment

Rosacea is treatable but not curable [s2t][edf][szn]

  1. Topical rosacea:

    • Avoid local irritation (UV light, hot/cold temperatures, wind, hot drinks, caffeine, exercise, spicy food, alcohol, soaps, alcoholic cleansers, tinctures, astrigents, abrasives and peeling agents. Only very mild soaps and diluted detergents are advised.

    • Color-correcting powders (make-up)

    • Sunscreen with SPF>30

    • Anti-inflammatory antibiotics: Tetracyclines, clindamycin, erythromycin, metronidazole gel

    • Imidazole

    • Ketoconazole cream (anti-inflammatory and immonusuppressive)

    • Drying lotions (sulphur lotion)

    • Topical retinoids (Isotretinoin)

    • Azelaic acid

    • Ivermectin cream

    • Brimonidine tartrate gel (alpha-2 agonist)

    • Oxymetazoline (topical alpha agonist)

    • Dapsone (severe, refractory rosacea)

    • Corticosteroids only used in rosacea fulminans

  2. Systemic rosacea:

    • Antibiotics: Tetracyclin 1-1.5g/day (alternative: Doxycycline/Erythromycin)

    • Isotretinoin 0.1-1.0mg/kg/day (side effects: dry eyes/blepharitis)

  3. Rosacea fulminans:

    • Oral corticosteroids: Prednisolon 1mg/kg/day for one week

    • Then Isotretinoin 0.2-0.5mg/kg/day with slow tapering of Prednisolon

  4. Ocular rosacea:

    • Lid hygiene

    • Lubricating eye drops: Fusidic acid gel (daily 1 to 2 times application on eyelids)

    • Topical antibiotics: Metronidazole 0.75% gel

    • Cyclosporine 0.05% eyedrops

  5. Remove telangiectasia:

    • Laser treatment

    • Surgical resection

    • Electrosurgery

Differential diagnoses

Acne, Carcinoid syndrome, Dermatomyositis, Drug side effects, Eczema, Mastocytosis, Mixed connective tissue disease, Perioral dermatitis, Photosensitivity, Polycythemia vera, Polymorphic light eruption, Sarcoidosis, Seborrheic dermatitis, Systemic lupus erythematosus


References

[1] Farshchian M, Daveluy S. Rosacea. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557574/

[2] http://emedicine.medscape.com/article/1071429; [Medscape]

[3] Cribier B. Pathophysiology of rosacea: redness, telangiectasia, and rosacea. Ann Dermatol Venereol. 2011 Nov;138 Suppl 3:S184-91.

[4] Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018 Aug;179(2):282-289.

[5] Saurat JH, Halioua B, Baissac C, Cullell NP, Ben Hayoun Y, Aroman MS, Taieb C, Skayem C. Epidemiology of acne and rosacea: A worldwide global study. J Am Acad Dermatol. 2024 May;90(5):1016-1018.

[6] Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017 Oct 4;9(1):e1361574.

[7] Abram K, Silm H, Oona M. Prevalence of rosacea in an Estonian working population using a standard classification. Acta Derm Venereol. 2010 May;90(3):269-73.

[8] Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med. 1997 Mar;90(3):144-50.

[9] [Clinical Dermatology 4.th Edition by Weller, Hunter, Savin and Dahl]

Scroll to top